GlassScriptPhysician profile
Sara Catherine Toth
NPI 1104130384
$5,174.01
in general payments reported to CMS, 2019-2025
25 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,637 · 2022: $1,466 · 2023: $1,028 · 2024: $782 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,487.00 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $489.55 | 2021-2024 | Myrisk, Bracanalysis Cdx |
| Incyte Corporation | $274.66 | 2022-2023 | Jakafi |
| Novo Nordisk INC | $260.27 | 2021-2022 | |
| Janssen Biotech, INC. | $241.42 | 2023-2024 | Darzalex, Tecvayli, Carvykti |
| Abbott Laboratories | $226.70 | 2021-2023 | 2nd Gen Centrimag Primary Console |
| G1 Therapeutics, INC. | $217.76 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $215.84 | 2022-2024 | Reblozyl, Augtyro, Opdualag |
| Adaptive Biotechnologies Corporation | $190.82 | 2023-2025 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $173.49 | 2023-2024 | Enhertu |
| Sobi, INC | $160.68 | 2022-2023 | |
| Daiichi Sankyo INC. | $150.67 | 2023-2024 | Enhertu |
| Pfizer INC. | $143.99 | 2023-2024 | |
| Abbvie INC. | $137.65 | 2022-2023 | |
| Glaxosmithkline, LLC. | $125.94 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $116.65 | 2025 | |
| Karyopharm Therapeutics INC. | $115.63 | 2023 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $108.40 | 2021 | |
| Seagen INC. | $99.74 | 2021-2022 | |
| Epizyme, INC. | $99.00 | 2022 | |
| Gilead Sciences, INC. | $49.99 | 2023 | Trodelvy |
| Amgen INC. | $29.14 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.08 | 2024 | Libtayo |
| Alnylam Pharmaceuticals INC. | $21.51 | 2025 | Onpattro |
| Aveo Pharmaceuticals, INC. | $15.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Toth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.